Jane Hook

3.6k citations

25 papers · 1.5k indexed · 1 hit paper · h-index 14

Reproductive Medicine top 0.5%
- Ovarian cancer diagnosis and treatment 12
Obstetrics and Gynecology top 1%
Surgery top 5%
- Intraperitoneal and Appendiceal Malignancies 6
Oncology top 10%
- Cancer Immunotherapy and Biomarkers 4
- CAR-T cell therapy research 3
- Vascular Tumors and Angiosarcomas 2
Pulmonary and Respiratory Medicine top 10%
- Sarcoma Diagnosis and Treatment 6
Rheumatology
- Bone Tumor Diagnosis and Treatments 3
Cancer Research
- Cancer Genomics and Diagnostics 3

Co-authors: Timothy Perren M Mascarenhas Selina Bannoo Stephen Dobbs Matthew Nankivell Gordon C. Jayson Jeremy Twigg David Luesley
Cited by: Reproductive Medicine Obstetrics and Gynecology Surgery
Journals: Journal of Clinical Oncology (7 papers)Annals of Oncology (5 papers)European Journal of Cancer (2 papers)
Partner nations: United Kingdom Netherlands Australia

In The Last Decade

Jane Hook

22 papers receiving 1.5k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Jane Hook

Since Specialization

Citations

This map shows the geographic impact of Jane Hook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Hook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Hook more than expected).

Fields of papers citing papers by Jane Hook

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Hook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Hook. The network helps show where Jane Hook may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jane Hook, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jane Hook Line = papers co-authored together Jane Hook links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Discriminative Accuracy of CHA2DS2-VASc Score, and Development of Predictive Accuracy Model Using Machine Learning for Ischemic Stroke Risk in Cardiac Amyloidosis and Atrial Fibrillation Cardiology Research ·Waqas Ullah,Maria Lup,김상렬,Salman Zahid,Nguyen Quang Lan,Palwasha Khan,隆誠後藤,José Massayoshi Miyagusko,Bernhard Kirschbaum,Said Ashraf,Jane Hook,Wb Zhu	2025	0
2	Virtual Reality + Heart Rate Variability Biofeedback Pain Effects in Older Adults with Knee Osteoarthritis Pain Management Nursing ·Jane Hook	2024	1
3	The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma BMC Cancer ·I. J. Joe,Pippa Corrie,Helen Marshall,Ruth Plummer,Christian H. Ottensmeier,Jane Hook,Sue Bell,Gurdeep S. Sagoo,David Meads,Janine Bestall,Galina Velikova,Ferdia A. Gallagher,M. B. Stevenson,Helen Howard,Ellen Mason,Eszter Katona,Louise Fairburn,Michelle Collinson,Zhanggui Hu,Sarah Danson	2021	18
4	805O ICON8: Overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment Annals of Oncology ·Andrew R. Clamp,Elizabeth C James,Iain A. McNeish,Andrew Dean,JW Kim,Dearbhaile M. O’Donnell,Jane Hook,Dolores Gallardo‐Rincón,C. Coyle,Sarah P. Blagden,James D. Brenton,Raj Naik,Timothy Perren,Sudha Sundar,Adrian Cook,Jonathan Badrock,Ann Marie Swart,Mahesh Parmar,Richard Kaplan,Jonathan A. Ledermann	2020	1
5	Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial The Lancet Oncology ·Sarah P. Blagden,Adrian Cook,Christopher Poole,高瀬澄夫,Iain A. McNeish,Andrew Dean,Jae‐Weon Kim,Dearbhaile M. O’Donnell,Jane Hook,Elizabeth C James,Ian R. White,Timothy Perren,Rosemary Lord,B. Ralph Chou,Helena Earl,Marcia Hall,Richard Kaplan,Jonathan A. Ledermann,Andrew R. Clamp	2020	17
6	MON-290 Ipilimumab Immune-Related ACTH Deficiency Is of Acute Onset and Severe Journal of the Endocrine Society ·H.S. Hota,Marilena Giannoudi,N. N. Kmuhametova,Julie Lynch,Elaine Dunwoodie,Jane Hook,Maria Marples,Robert Murray	2020	0
7	Are we over-treating with checkpoint inhibitors? British Journal of Cancer ·Sarah Danson,Jane Hook,Helen Marshall,M. B. Stevenson,Sue Bell,Zhanggui Hu,Pippa Corrie	2019	13
8	ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis Annals of Oncology ·Rahmath Fida,Iain A. McNeish,Andrew Dean,David Gallardo,T. A. Carter,Dearbhaile M. O’Donnell,Jane Hook,C. Coyle,Sarah P. Blagden,James D. Brenton,Raj Naik,Timothy Perren,Sudha Sundar,Adrian Cook,Elizabeth C James,Ann Marie Swart,Sally Stenning,Richard Kaplan,Jonathan A. Ledermann	2017	38
9	ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer Annals of Oncology ·Elizabeth C James,Jane Hook,SP Stenning,Adrian Cook,C. Coyle,Jennifer Petrie,Richard Kaplan,Iain A. McNeish,Timothy Perren,Rajesh R. Naik,Susana Banerjee,Jonathan A. Ledermann,Andrew R. Clamp	2016	0
10	Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trialbreakdown → The Lancet ·Sean Kehoe,Jane Hook,Matthew Nankivell,Gordon C. Jayson,Henry C Kitchener,Tito Lopes,David Luesley,Timothy Perren,Selina Bannoo,M Mascarenhas,Stephen Dobbs,Sharadah Essapen,Jeremy Twigg,Jonathan Herod,Glenn McCluggage,Mahesh Parmar,Lisete Sofia dos Santos Lopes	2015	945
11	Event-free survival and overall survival in 2,253 patients with osteosarcoma registered to EURAMOS-1. Journal of Clinical Oncology ·Sigbjørn Smeland,Jeremy Whelan,Stefan Bielack,Neyssa Marina,Gordana Jovic,Trude Butterfaß‐Bahloul,Gabriele Calaminus,Mikael Eriksson,Hans Gelderblom,Richard Görlick,Pancras C.W. Hogendoorn,Jane Hook,Leo Kager,Mark Krailo,Thomas Kühne,R. Lor Randall,Kirsten Sundby Hall,Lisa A. Teot,Matthew R. Sydes,Mark L. Bernstein,(unknown)	2015	2
12	Maintenance therapy in ovarian cancer Current Opinion in Oncology ·Saira Khalique,Jane Hook,Jonathan A. Ledermann	2014	22
13	ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology ·Jane Hook,Sally Stenning,James D. Brenton,Stan B. Kaye,Iain A. McNeish,Raj Naik,Timothy Perren,Jennifer Petrie,Laura Farrelly,Andrew Dean,Dearbhaile M. O’Donnell,Dolores Gallardo Rincón,Jae‐Weon Kim,Jonathan A. Ledermann,Andrew R. Clamp,(unknown)	2014	3
14	MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 “good response” randomization. Journal of Clinical Oncology ·Stefan Bielack,Sigbjørn Smeland,Jeremy Whelan,Neyssa Marina,Jane Hook,Gordana Jovic,Mark Krailo,Trude Butterfaß‐Bahloul,Thomas Kühne,Mikael Eriksson,Lisa A. Teot,Hans Gelderblom,Leo Kager,Kirsten Sundby Hall,Richard Görlick,R. Lor Randall,Pancras C.W. Hogendoorn,Gabriele Calaminus,Matthew R. Sydes,Mark L. Bernstein	2013	11
15	Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup European Journal of Cancer ·Anne McTiernan,Rachel C. Jinks,Matthew R. Sydes,Barbara Uscinska,Jane Hook,M. van Glabbeke,Vivien Bramwell,Ian Lewis,Antonïe H.M. Taminiau,M. Nooij,Pancras C.W. Hogendoorn,Hans Gelderblom,Jeremy Whelan	2011	40
16	Biomarkers in the development of anti-angiogenic therapies for ovarian cancer Cancer Treatment Reviews ·Fharat Raja,Jane Hook,Jonathan A. Ledermann	2011	16
17	Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials Annals of Oncology ·Jeremy Whelan,Rachel C. Jinks,Anne McTiernan,Matthew R. Sydes,Jane Hook,Leonardo Trani,Barbara Uscinska,V. Bramwell,Ian Lewis,M. Nooij,M. van Glabbeke,R. J. Grimer,Pancras C.W. Hogendoorn,A. H. M. Taminiau,Hans Gelderblom	2011	156
18	Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer European Journal of Cancer ·Rohini Sharma,Jane Hook,Munish Kumar,Hani Gabra	2008	71
19	Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecologic Oncology ·Mark Linch,Amoon Mohammed Ali Albatool,Jane Hook,Yolanda Barbáchano,M. Gore,Stuart Kaye	2008	18
20	The impact of molecular genetic diagnosis on the management of women with hCG-producing malignancies Gynecologic Oncology ·Rosemary A. Fisher,Philip Savage,Ting-Ru Yang,Jane Hook,Neil J. Sebire,Iain Lindsay,Michael J. Seckl	2007	67

About Jane Hook

Jane Hook is a scholar working on Reproductive Medicine, Cancer Research, Oncology, Obstetrics and Gynecology and Pulmonary and Respiratory Medicine, having authored 25 papers that have together received 1.5k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (12 papers), Intraperitoneal and Appendiceal Malignancies (6 papers), Sarcoma Diagnosis and Treatment (6 papers), Cancer Immunotherapy and Biomarkers (4 papers), CAR-T cell therapy research (3 papers), Bone Tumor Diagnosis and Treatments (3 papers), Cancer Genomics and Diagnostics (3 papers) and Vascular Tumors and Angiosarcomas (2 papers). The work is most often cited by research in Reproductive Medicine (1.0k citations), Obstetrics and Gynecology (486 citations), Surgery (706 citations), Oncology (417 citations) and Pulmonary and Respiratory Medicine (292 citations). Jane Hook has collaborated with scholars based in United Kingdom, Netherlands and Australia. Frequent co-authors include Timothy Perren, M Mascarenhas, Selina Bannoo, Stephen Dobbs, Matthew Nankivell, Gordon C. Jayson, Jeremy Twigg, David Luesley, Jonathan Herod and Sean Kehoe. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Gynecologic Oncology and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact